![]() |
CDB323 trial discontinued
Biogen Idec and Belgian biopharmaceutical Co UCB SA discontinued the Phase II clinical trial of CDB323 treatment for relapsing-remitting Multiple Sclerosis today, saying no clinically relevant benefit was seen for patients after six months in a trial of CDB323 compared with placebo...
http://www.nasdaq.com/aspx/stock-mar...osis-treatment |
This drug was an oral Alpha4 integrin blocker - think oral Tysabri. Elan has their own small molecule Alpha4 integrin blocker in Phase I trials.
Chris |
All times are GMT -5. The time now is 11:59 AM. |
Powered by vBulletin Copyright ©2000 - 2025, Jelsoft Enterprises Ltd.
vBulletin Optimisation provided by
vB Optimise (Lite) -
vBulletin Mods & Addons Copyright © 2025 DragonByte Technologies Ltd.